A limited company with a mainly public capital
The LFB Group, a French biopharmaceutical company, has a limited company status with a mainly public capital. The Group is currently fully owned by the French state. The LFB Group is active on a competitive market and bids for hospital tenders like other pharmaceutical companies.
LFB BIOMEDICAMENTS is the French subsidiary specialized in the manufacture and marketing of plasma-derived medicinal products.
LFB BIOTECHNOLOGIES is the subsidiary specialized in the group’s biotechnology activities and is composed of:
• rEVO BIOLOGICS, American subsidiary, specialized in innovative recombinant therapy
• CELLforCURE, French subsidiary, specialized in cell therapy
• LFB BIOMANUFACTURING, French subsidiary, specialized in bioproduction by cell culture with a production unit located in Alès (Gard).
LFB HEMODERIVADOS E BIOTECNOLOGIA markets plasma-derived medicinal products in Brazil. Its own subsidiary LFB TECNOLOGIA Ltda coordinates the technology transfer project with Brazil.
EUROPLASMA, subsidiary integrated in 2010, specialises in collecting plasma and manages 8 collection centers in Europe.
The LFB group is member of the G5, made up of main French pharmaceutical companies, also member of “France Biotech” board of Directors, and of IPFA (International Plasma Fractionation Association).